AsiaNet 88229

EMERYVILLE, Calif., Feb. 24, 2021 /PRNewswire=KYODO JBN/ --

   -- Seasoned finance executive has raised $1B+ in equity financing to scale

     biofacturing platform for commercial markets

Biofacturing leader Zymergen (

https://c212.net/c/link/?t=0&l=en&o=3077202-1&h=1965526795&u=http%3A%2F%2Fwww.zymergen.com%2F&a=Zymergen

) today announced it has promoted Enakshi (Ena) Singh to Chief Financial

Officer. Singh has helped Zymergen close more than $1B in equity financing and

$100M in debt since joining Zymergen as vice president of finance in 2014,

fueling the company's early growth, testing, de-risking, and product

development. Singh's promotion comes as Zymergen moves into commercial and

operational scaling, following the $300M in new investment (

https://c212.net/c/link/?t=0&l=en&o=3077202-1&h=2047817159&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fzymergen-takes-aim-at-3-trillion-chemical--materials-industry-with-300-million-in-new-funding-301125840.html&a=%24300M+in+new+investment

) last year, which has further accelerated their discovery and production of

novel, high-performance materials.

Photo - https://mma.prnewswire.com/media/1443697/Zymergen_CFO_Ena_Singh.jpg

Logo - https://mma.prnewswire.com/media/1218528/Zymergen_Logo.jpg

"Ena has a proven track record earning the confidence of some of the leading

and most demanding global investors to embrace the power and opportunity of

biofacturing," says Josh Hoffmann, Zymergen CEO. "Our business is not your

typical cloud or biotech platform, and Ena has charted a masterful financial

course for a new kind of science and technology company. She is the right

person to lead financial strategy for our next chapter, focusing on expanding

our commercial operations and sales."

Singh previously served as SVP of asset management at Mubadala, Abu Dhabi's

$230B sovereign wealth fund, where she led complex semiconductor investments

involving specialized manufacturing and unique investment and scaling models

that are a direct parallel for Zymergen's biofacturing platform. Previously,

she was the VP of technology investment banking at Merrill Lynch and an analyst

for Latin American investment banking at Salomon Smith Barney. She earned a BA

in economics at Cornell University and an MBA at MIT Sloan School of Management.

"Ena's ability to seamlessly move between investors and customers, coupled with

her deep understanding of Zymergen's business model and technology platform,

has garnered enthusiastic support from the board and investors alike," said

Sandi Peterson, Zymergen board member and former Group Worldwide Chairwoman of

Johnson & Johnson. "She brings the right experience at the right time to lead

Zymergen's expansion into commercial markets."

"In seven years, Zymergen has grown from an idea to a thriving platform

company, with one product in market and many more on the way," said Singh.

"Zymergen is winning customer confidence that we can discover breakthrough

materials, and also scale and deliver them to demanding markets like

electronics, consumer care and agriculture. Innovators seek new materials to

accomplish today's toughest challenges - and Zymergen's biofacturing platform

is delivering."

Based on our early experience, Zymergen develops and launches high-performance

products more sustainably and for a fraction of the cost and time that it

typically takes using legacy petrochemical techniques. A unique combination of

biology, chemistry, software and automation fuels Zymergen's high-throughput

biodiscovery engine, enabling the company to discover, design and commercialize

new materials at unprecedented speed.

About Zymergen

Zymergen is a biofacturing company using biology to reimagine the world.

Zymergen partners with nature to create, develop and manufacture breakthrough

products and materials across industries - from agriculture to electronics,

consumer care to pharmaceuticals, and more. The company produces a suite of

high performing, sustainable materials in use today, delivering value for

Fortune 500 companies with over $1 billion worth of products using Zymergen

microbial innovations sold to date. Learn more at http://zymergen.com.

SOURCE: Zymergen

CONTACT:  zymergen@methodcommunications.com